Bolt Biotherapeutics to Present at 20th Annual Needham Virtual Healthcare Conference
April 08 2021 - 7:00AM
Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biotechnology
company pioneering a new class of immuno-oncology agents that
combine the targeting precision of antibodies with the power of
both the innate and adaptive immune systems, today announced that
Randall C. Schatzman, Ph.D., Chief Executive Officer, will present
a company overview at the 20th Annual Needham Virtual Healthcare
Conference on Thursday, April 15, 2021 at 10:15 AM ET.
A live webcast of the presentation will be available on the
Events and Presentations page of Bolt’s website at www.boltbio.com.
An archived replay will be available for 90 days following the
event.
About Bolt Biotherapeutics, Inc.Bolt
Biotherapeutics, Inc. is a clinical-stage biotechnology company
pioneering a new class of immuno-oncology agents that combine the
targeting precision of antibodies with the power of both the innate
and adaptive immune systems. Bolt’s proprietary Boltbody™
Immune-stimulating Antibody Conjugates (ISACs) approach uses
immunostimulants to engage and activate myeloid cells that directly
kill tumor cells. This leads to the conversion of immunologically
“cold” tumors to “hot” tumors. Bolt’s lead candidate, BDC-1001, is
a Boltbody ISAC comprised of a HER2-targeting biosimilar of
trastuzumab conjugated to one of Bolt’s proprietary TLR7/8 agonists
currently undergoing phase 1/2 clinical testing for the treatment
of patients with HER2-expressing solid tumors. Bolt is also
advancing an additional Boltbody ISAC product candidate targeting
CEA (BDC-2034).
Media Contacts: Maggie Beller or David Schull
Russo Partners, LLC 646-942-5631 maggie.beller@russopartnersllc.com
david.schull@russopartnersllc.com
Investor Relations Contact:Sarah McCabeStern
Investor Relations, Inc.212-362-1200sarah.mccabe@sternir.com
Bolt Biotherapeutics (NASDAQ:BOLT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Bolt Biotherapeutics (NASDAQ:BOLT)
Historical Stock Chart
From Apr 2023 to Apr 2024